Key Evidence #1
observationalPublic scholarly dataCitation signal: 1116
“Hit-and-run” treatment with senolytics, which in the case of D’+ Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans.
Tier-BPublic-ready6/12/2026
Quercetin
Blood pressure and vascular health markers is closer to a research marker, so it should be read separately from a directly felt benefit.
Representative tier calculated from paper evidence that passed the collection audit.
Papers analyzed
20
Caution signal
Low
Representative score
59.4
Blood pressure and vascular health markersNutrient status markersImmune and respiratory support
Main benefit evidence
The representative ingredient tier is calculated from these target-level evidence groups.
Blood pressure and vascular health2 studiesTier-BBlood pressure and vascular health markersFairly consistent positive signal in studiesResearch marker focusSupplement contextThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Blood pressure and vascular health
2 studiesTier-B
Blood pressure and vascular health markers
Fairly consistent positive signal in studiesResearch marker focusSupplement context
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit.
Closer to a research marker than a directly felt benefit.
Open metrics
>Blood pressure and vascular markers
No direct rate reported. Read direction and evidence strength together.
Evidence score
58.0
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Nutrient status2 studiesTier-CNutrient status markersSome positive signal observedResearch marker focusSupplement contextThis card is closer to a measured biomarker or lab outcome than a directly felt user benefit.Closer to a research marker than a directly felt benefit.Open metrics>
Nutrient status
2 studiesTier-C
Nutrient status markers
Some positive signal observedResearch marker focusSupplement context
This card is closer to a measured biomarker or lab outcome than a directly felt user benefit.
Closer to a research marker than a directly felt benefit.
Open metrics
>Nutrient status and deficiency markers
No direct rate reported. Read direction and evidence strength together.
Evidence score
44.3
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Immune and respiratory health1 studiesTier-CImmune and respiratory supportSome positive signal observedFelt benefit focusSupplement contextPotential benefit studied in Immune and respiratory health.Open metrics>
Immune and respiratory health
1 studiesTier-C
Immune and respiratory support
Some positive signal observedFelt benefit focusSupplement context
Potential benefit studied in Immune and respiratory health.
Open metrics
>Immune and respiratory support
No direct rate reported. Read direction and evidence strength together.
Evidence score
44.0
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Condition-specific evidence1 studiesTier-CCondition-specific health context in a specific contextSome positive signal observedResearch marker focusSupplement contextThis result was studied for Condition-specific health context in a narrower population or condition-specific context. It should not be generalized as an everyday supplement effect.Closer to a research marker than a directly felt benefit.Open metrics>
Condition-specific evidence
1 studiesTier-C
Condition-specific health context in a specific context
Some positive signal observedResearch marker focusSupplement context
This result was studied for Condition-specific health context in a narrower population or condition-specific context. It should not be generalized as an everyday supplement effect.
Closer to a research marker than a directly felt benefit.
Open metrics
>Condition-specific health context
No direct rate reported. Read direction and evidence strength together.
Evidence score
44.0
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Blood lipids1 studiesTier-CCholesterol and triglyceridesSome positive signal observedFelt benefit focusSupplement contextPotential benefit studied in Blood lipids.Open metrics>
Blood lipids
1 studiesTier-C
Cholesterol and triglycerides
Some positive signal observedFelt benefit focusSupplement context
Potential benefit studied in Blood lipids.
Open metrics
>Cholesterol and triglycerides
No direct rate reported. Read direction and evidence strength together.
Evidence score
22.8
Score reflects signal strength. Tier also considers paper count, repetition, and study context.
Recent research
Updated This Month10 new papers
10 new papers were added in this period. No new risk signal was identified.
What's new
10 new papers were added.No new risk signal was identified.
Most notable recent finding
This is the most meaningful new study in the latest update.
Why it mattersIt ranked highest among the newly collected papers for this ingredient in the latest update.
View paperStudy dosage range (reference only)
Lower dose
50
mg/dayHigher dose
1000
mg/dayDosages used in research papers, shown as reference context.
Not personal dosing instructions, recommendations, or safety limits.
Key cautions to review
Standalone side-effect signals and combination cautions are listed separately.
Caution index
0.3
Caution band: Low
Caution signals
0
Side effects + combos + curated rules
Key precautions
No combination caution signal is clear enough to show right now. This does not guarantee safety.
Standalone side effects, combination cautions, and positive combos are separated below.
Side-effect and combination signals
No standalone side-effect or combination signal is currently clear enough to show from the collected papers. This does not mean there is no concern.
Evidence summaries
Paper IDs and full lists are private. Only study types and summaries are shown.
Key Evidence #2
observationalPublic scholarly dataCitation signal: 238
A more soluble formulation of quercetin based on lecithin, Quercet in Phytosome, has recently been developed, and was found to facilitate the attainment of very high plasma levels of quERCetin when the novel formulation was administered orally in human volunte
Key Evidence #3
observationalPublic scholarly dataCitation signal: 214
Intermittently-dosed D + Q in patients with IPF is feasible and generally well-tolerated and further prospective studies, such as a larger RCT, are needed to confirm the safety and efficacy.
3 more summariesLimited representative sample by study type.>
Public scholarly dataCitation signal: 208
observationalCNS penetrance of D was observed with outcomes supporting safety, tolerability and feasibility in patients with AD, and biomarker data provided mechanistic insights of senolytic effects that need to be confirmed in fully powered, placebo-controlled studies.
Public scholarly dataCitation signal: 160
observationalThe investigated phenolic compounds seem to positively mediate bone metabolism and osteoclast-related pathologies and could represent a possible application to improve the osteogenic processes and osseointegration.
Public scholarly dataCitation signal: 144
observationalSubstantial reduction in URTI was experienced in subjects ≥ 40 years of age ingesting 1000 mg quercetin/day and rating themselves as physically fit, and the strongest interaction effect with group status was self‐reported fitness level.
Quercetin
arrow_backBack to listEvidence score: 59.4|Caution index: 0.3